Allied Corp Signs Agreement to Enable Offering of GMP Certified Products
KELOWNA, British Columbia, May 05, 2023 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
Year: 2023
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023
Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30...
Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Data to support the development of EPI-321 as a one-time gene therapy treatment for facioscapulohumeral muscular dystrophy (FSHD)SOUTH SAN FRANCISCO,...
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
The Company’s entire cultivation facility has been mobilized to service supply agreementsVANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) --...
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology...
Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain
Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment...
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ETSAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor...
Pharmafusion Launches New Tableau Accelerator for the Pharmaceutical Industry
Using Pharmafusion’s new Tableau accelerator, the pharma industry can now unlock insights and context from pharmaceutical dataEAST NORRITON, Pa., May...
Yield10 Bioscience to Announce First Quarter 2023 Financial Results and Host a Conference Call on Wednesday, May 10, 2023
WOBURN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company,...
Privia Health Announces Pricing of Secondary Offering of $689 Million of Common Stock
– Investors include Durable Capital Partners LP and Rubicon Founders LLCARLINGTON, Va., May 04, 2023 (GLOBE NEWSWIRE) -- Privia Health...
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE,...
Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH,...
Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023
DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on...
IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023
LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary...
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality...
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
First fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy...
ReWalk Robotics to Provide First U.S. Demonstrations of Groundbreaking Stairs-Enabled Exoskeleton Technology
ReWalk Robotics will unveil its innovative new exoskeleton to the public at the upcoming Abilities Expo in New York, with...
SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study
- 72 Acute Myeloid Leukemia and Lymphoma High-Risk Advanced Patients Enrolled: 94% Alive at Last Assessment Indicating Favorable Survival Benefit...
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...